Fig. 1: IGF2BP3 promotes paclitaxel resistance in EC cells.
From: The role of IGF2BP3/SPOP/c-Myc loop in paclitaxel resistance of endometrial cancer
A PCA map of control and paclitaxel-resistant EC cells of RNA-seq. B RNA-seq sequencing analysis of DEGs between the control group and the paclitaxel-resistant EC cells group. C Venn analysis was performed on the highly expressed genes from the RNA-seq of paclitaxel-resistant Ishikawa cells, the highly expressed genes in paclitaxel-resistant cells from GEO228106, the highly expressed genes in paclitaxel-resistant cells from GEO50831, and the highly expressed genes in TCGA’s UCEC. D The expression of IGF2BP3, MSH2, and NUDT3 mRNA in control and paclitaxel-resistant EC cells. E The IC50 of paclitaxel in EC cells with IGF2BP3 overexpression. F The IC50 of paclitaxel in EC cells with IGF2BP3 knockout. G Regimen of paclitaxel injection in NOD-SCID nude mice (Created in BioRender. Zhang, H. (2025) https://BioRender.com/3xsuwvq, Agreement number: FY283DMA1N). H Representative photographs of xenograft tumors of NC + NS, sh-IGF2BP3 + NS, NC+ paclitaxel, and sh-IGF2BP3+ paclitaxel. I The weight of xenograft tumors of NC + NS, sh-IGF2BP3 + NS, NC+ paclitaxel, and sh-IGF2BP3+ paclitaxel. J Relative growth volume of xenograft tumors of NC + NS, sh-IGF2BP3 + NS, NC+ paclitaxel, and sh-IGF2BP3+ paclitaxel at 24 days. K Immunohistochemical staining of xenograft tumors of NC + NS, sh-IGF2BP3 + NS, NC+ paclitaxel, and sh-IGF2BP3+ paclitaxel, Scale bar, 20 μm. Data are shown as mean ± SD (n ≥ 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
